Stockreport

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer [Yahoo! Finance]

Nanobiotix S.A. - ADSs  (NBTX) 
PDF 85% (11/13) disease control rate (DCR) 69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responses Recruitment of 17 additional patients [Read more]